Quantbot Technologies LP Purchases 71,888 Shares of Integra LifeSciences Holdings Corporation $IART

Quantbot Technologies LP lifted its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 362.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 91,713 shares of the life sciences company’s stock after purchasing an additional 71,888 shares during the period. Quantbot Technologies LP owned 0.12% of Integra LifeSciences worth $1,125,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its holdings in Integra LifeSciences by 205.9% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after buying an additional 2,108 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $73,000. EMC Capital Management acquired a new stake in shares of Integra LifeSciences in the second quarter worth $75,000. CWM LLC grew its stake in shares of Integra LifeSciences by 32.6% in the second quarter. CWM LLC now owns 8,834 shares of the life sciences company’s stock worth $108,000 after acquiring an additional 2,170 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its position in Integra LifeSciences by 6,017.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock worth $124,000 after acquiring an additional 9,929 shares during the period. Institutional investors own 84.78% of the company’s stock.

Insiders Place Their Bets

In other news, Director Jeffrey A. Graves purchased 9,000 shares of the company’s stock in a transaction on Wednesday, November 5th. The shares were purchased at an average cost of $11.35 per share, with a total value of $102,150.00. Following the completion of the transaction, the director owned 41,086 shares of the company’s stock, valued at $466,326.10. The trade was a 28.05% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on IART shares. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 1st. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Citigroup lowered their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research note on Friday, October 31st. JPMorgan Chase & Co. raised their target price on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Finally, Truist Financial restated a “hold” rating and set a $13.00 price target (down previously from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $15.00.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $13.02 on Tuesday. Integra LifeSciences Holdings Corporation has a one year low of $10.87 and a one year high of $27.13. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.14 and a quick ratio of 1.80. The stock’s 50-day moving average is $13.41 and its 200-day moving average is $13.38. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -2.02 and a beta of 1.06.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11. The company had revenue of $402.06 million during the quarter, compared to the consensus estimate of $414.31 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.41 EPS. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.